Ophthalmology Drug Discovery Service
As an innovative company in the field of neuroscience, Creative Biolabs has successfully built an advanced platform and a professional team. We are committed to providing one-stop ophthalmic research related services to customers all over the world to speed up your project progress.
Overview of Ocular Conditions
The eye is a vital and sensitive organ, but it is prone to many diseases. Eye diseases are chronic diseases that affect millions of people around the world, resulting in significant health and economic burden. In general, eye conditions are closely associated with visual disturbances, resulting in progressive loss of vision. Glaucoma, diabetic retinopathy, macular edema, or cataracts are the most common posterior segment lesions, and their progression can lead to visual impairment or blindness. A variety of factors can adversely affect the eyes. In addition to genetic factors, poor eye habits, injuries, aging, and microbial infections can all lead to the occurrence of ocular conditions.
Fig.1 Schematic illustrations of some age-related ocular disorders. (Lorenzo-Veiga, 2021)
Therapeutic Approaches
Drugs occupy an indispensable role in the treatment of ocular diseases, but drug delivery still faces many challenges. While intravitreal injection is beneficial for delivering the drug to the posterior segment of the eye, it is often accompanied by side effects. Furthermore, existing ocular drug delivery systems are inefficient. Thus, nanotechnology provides a powerful platform for developing new and more effective treatments. It's worth noting that surgical therapy can also help reduce symptoms of ocular conditions. More importantly, some other modalities, such as cell therapy and gene therapy, have also achieved exciting results in some ocular conditions, which provide a new direction for the development of new therapeutic strategies.
Models of Ocular Conditions
Over the past few years, many ocular barrier cell culture models have been established. These in vitro models are emerging as powerful tools for investigating drug transport into ocular tissues. In addition, these models have important implications for the study of pathological ocular diseases, cellular physiology, drug uptake and transport, and pathological conditions.
Animals constitute the most powerful models for testing hypotheses and treatments. Animal models have contributed to elucidating some mechanisms of human disease. These models are critical in common areas of ocular research, including intraocular neoplasia, keratitis, cataracts, glaucoma, and retinal dystrophies. They are integral in developing all the latest molecular-based therapies, such as gene therapy, optogenetic retinal, and stem cell therapies.
Creative Biolabs is committed to providing customized services for a variety of diseases, including but not limited to:
- Age-Related Macular Degeneration
- Conjunctivitis
- Dry eye
- Glaucoma
- Keratitis
- Posterior Capsule Opacification
- Diabetic Macular Edema
- Retinal Vein Occlusion
- Geographic Atrophy
Services for ophthalmology Research
- In Vitro Services
- In Vivo Services
- Ex Vivo Services
- Discovery Services
- Development Services
- Mechanism of Action (MoA) Studies
With our professional knowledge and rich experience, Creative Biolabs is confident to provide you with cost-effective services according to your project needs. Please contact us to discuss your plans for sound advice and professional assistance.
Reference
- Lorenzo-Veiga, B.; et al. Age-related ocular conditions: Current treatments and role of cyclodextrin-based nanotherapies. International Journal of Pharmaceutics. 2021, 603: 120707.
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1760) (Cat#: NRP-0422-P1760)
- iNeuMab™ Anti-Alpha Synuclein BBB Shuttle Antibody (NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Anti-pTau Antibody (NRP-0422-P1719) (Cat#: NRP-0422-P1719)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P515) (Cat#: NRP-0422-P515)
- iNeuMab™ Anti-GARP Antibody (NRP-0422-P1639) (Cat#: NRP-0422-P1639)
- iNeuMab™ Anti-TREM2 BBB Shuttle Antibody (NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- iNeuMab™ Anti-TNFα BBB Shuttle Antibody (NRZP-1022-ZP4105) (Cat#: NRZP-1022-ZP4105)
- iNeuMab™ Anti-FGFR1 Antibody (NRP-0422-P1244) (Cat#: NRP-0422-P1244)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Mouse Microglia Cell Line BV-2, Immortalized (Cat#: NCL2110P153)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- Human Neurons Isolated from Cortex (Cat#: NCL-21P6-023)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Human Brain Vascular Adventitial Fibroblasts (Cat#: NCL-21P6-014)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV2/9-hEF1a-fDIO-eNpHR 3.0-mCherry-WPRE-pA (Cat#: NTA-2012-ZP78)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)